Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics

Nucleic Acid Therapeutics
Cindy L BermanHusam S Younis


This document was prepared by the Safety Pharmacology Subcommittee of the Oligonucleotide Safety Working Group (OSWG), a group of industry and regulatory scientists involved in the development and regulation of therapeutic oligonucleotides. The mission of the Subcommittee was to develop scientific recommendations for the industry regarding the appropriate scope and strategies for safety pharmacology evaluations of oligonucleotides (ONs). These recommendations are the consensus opinion of the Subcommittee and do not necessarily reflect the current expectations of regulatory authorities. 1) Safety pharmacology testing, as described in the International Conference on Harmonisation (ICH) S7 guidance, is as applicable to ONs as it is to small molecule drugs and biotherapeutics. 2) Study design considerations for ONs are similar to those for other classes of drugs. In general, as with other therapeutics, studies should evaluate the drug product administered via the clinical route. Species selection should ideally consider relevance of the model with regard to the endpoints of interest, pharmacological responsiveness, and continuity with the nonclinical development program. 3) Evaluation of potential effects in the core battery (cardi...Continue Reading


May 20, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christopher M C Mattice, Maria C DeRosa
Nov 11, 2017·Nucleic Acid Therapeutics·Daniel CapaldiJeffrey Foy
Feb 19, 2016·Science Translational Medicine·Janika ViereckThomas Thum
Aug 29, 2020·Nucleic Acid Therapeutics·Daniel CapaldiRainer Wechselberger


Aug 26, 1998·The American Journal of Cardiology·W R Daley
Nov 13, 1998·Journal of Pharmaceutical Sciences·R J BoadoW M Pardridge
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·B M TylerE Richelson
Apr 3, 2001·American Journal of Respiratory and Critical Care Medicine·S AliJ W Nyce
Jun 3, 2004·Journal of Pharmacological and Toxicological Methods·A P HarrisonM A Unmack
Jun 15, 2005·Journal of Pharmacological and Toxicological Methods·Susan G Emeigh Hart
May 30, 2008·Journal of Pharmacological and Toxicological Methods·Hugo M VargasJean-Pierre Valentin
Aug 2, 2008·The Journal of Toxicological Sciences·Takahiro NakazawaTohru Inoue
Sep 2, 2008·Pulmonary Pharmacology & Therapeutics·Alain GuimondNicolay Ferrari
May 12, 2009·Journal of Pharmacological and Toxicological Methods·Ray W ChuiHugo M Vargas
Jan 30, 2010·International Journal of Toxicology·Peter SazaniStephen B Shrewsbury
Feb 10, 2010·British Journal of Pharmacology·Chris E PollardJ-P Valentin
Jul 21, 2010·The Journal of Physiology·Matthew D PerryJohn Mitcheson
Dec 15, 2010·Advanced Drug Delivery Reviews·Ben ForbesRon K Wolff
Jul 24, 2012·Advanced Drug Delivery Reviews·János SzebeniRudolf Urbanics
Sep 20, 2012·Physiological Reviews·Jamie I VandenbergAdam P Hill
Oct 30, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Gordon C HardSamuel M Cohen
Nov 23, 2012·Expert Opinion on Drug Safety·Hugo M VargasMichael J Engwall
Mar 23, 2013·Journal of Pharmacological and Toxicological Methods·Roger D Porsolt
May 21, 2013·Journal of Pharmacological and Toxicological Methods·Simon AuthierMichael K Pugsley
Nov 12, 2013·Journal of Pharmacological and Toxicological Methods·Tae-Won KimScott Henry

Related Concepts

Cholera Infantum
Nonhuman primate
Degenerative Diseases, Spinal Cord
Respiratory Physiology
Research Methodology
Respiratory System
Safety Pharmacology

Related Feeds


Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.